News & Updates

Show Multimedia Only

Spironolactone does not up risk of breast cancer recurrence

30 Sep 2020

Use of spironolactone does not increase the risk of female breast cancer recurrence and may be considered for the treatment of alopecia in survivors, results of a recent study have shown.

Spironolactone does not up risk of breast cancer recurrence

30 Sep 2020

Abrocitinib holds promise for moderate-to-severe AD

30 Sep 2020 by

The investigational JAK1* selective inhibitor abrocitinib was effective and well-tolerated in adolescents and adults with moderate-to-severe atopic dermatitis (AD), the phase III JADE MONO-2 trial has shown.

Abrocitinib holds promise for moderate-to-severe AD

30 Sep 2020

News & Updates

Filter by Specialty:

Specialty:

Spironolactone does not up risk of breast cancer recurrence

Spironolactone does not up risk of breast cancer recurrence

Abrocitinib holds promise for moderate-to-severe AD

Abrocitinib holds promise for moderate-to-severe AD